CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 562 enrolled
Drug / intervention
Dexamethasone Palmitate +1 moredrug
Likely dose
Dexamethasone Palmitate 21 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05920967
NCT05920967N/ACompleted

Effect of Continuous Paravertebral Nerve Block Combined With Dexamethasone Palmitate vs Combined With Dexamethasone Sodium Phosphate on Chronic Postoperative Pain in Patients Undergoing Minimally Invasive Cardiac Surgery

Xijing Hospital·interventional·Posted Jun 27, 2023·Updated May 28, 2026

In Brief

A clinical study evaluating Dexamethasone Palmitate and Dexamethasone Sodium Phosphate for Chronic Postoperative Pain. Completed, enrolled 562 participants across 1 site.

Detailed Summary

The goal of this single-center, prospective, double-blind randomized controlled clinical trial is to explore preventive interventions for chronic postoperative pain (CPSP) in patients undergoing minimally invasive cardiac surgery. The main questions it aims to answer is: the incidence of CPSP is high and severe, and there is no safe and effective method for prevention and treatment. The participants in the dexamethasone palmitate (DXP) group will receive a single paravertebral space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml. The participants in dexamethasone sodium phosphate (DXM) group will receive a single infusion of a paravertebral space first dose of 21 ml of analgesic containing 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml. Then both groups use a continuous paravertebral nerve block pump for postoperative analgesia. The liquid of the pump is 250 ml 0.2 percentage ropivacaine. The background of the pump is set to 5 ml/h and PCA is set to 5 ml at an interval of 30 min.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedJun 27, 2023
Enrollment StartJul 11, 2023
Primary CompletionSep 18, 2024
Study CompletionOct 30, 2025
TodayJul 1, 2026
Enrollment to primary: 1.2 yearsPosted 3.0 years ago

Interventions

Dexamethasone Palmitatedrug

a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone palmitate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.

Dexamethasone Sodium Phosphatedrug

a single paraverteal space infusion of 21 ml of the first dose of analgesia, consisting of 0.5 percentage ropivacaine 20 ml and dexamethasone sodium phosphate 1ml. Then, a continuous paraverteal nerve block pump was connected for postoperative analgesia. The liquid of the pump was 250 ml 0.2 percentage ropivacaine. The background of the pump was set to 5 ml/h and PCA was set to 5 ml at an interval of 30 min.